Investigation of Prognostic Factors and Survival without Recurrence in Patients with Breast Cancer

Document Type : Original Article


1 Department of General Surgery, School of Medicine, Research Center for Health Sciences, Shiraz University of Medical Sciences, Shiraz, Iran

2 Department of Epidemiology, School of Health, Shiraz University of Medical Sciences, Shiraz, Iran

3 Department of Epidemiology, School of Health, Shiraz University of Medical Sciences, Shiraz; Deputy of Research, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran


Background: One of the major consequences of breast cancer is the recurrence of the disease. The objective of present study was to estimate the 7-year survival without recurrence as well as the effective prognostic factors in recurrence. Materials and Methods: This historical cohort survival analysis was conducted on 1329 patients diagnosed with breast cancer in Motahari Breast Clinic, Shiraz, Iran between 2004 and 2011. We estimated the rate of survival without recurrence through the Kaplan–Meier method and the difference between the survival curves was investigated using the log-rank test. Furthermore, Cox regression model was used to model the effective factors in local recurrence as well as metastasis. Results: The mean age of the patients was 54.8 ± 11.4 years. Estrogen receptor positive, progesterone receptor positive, and human epidermal growth factor receptor-2 positive were observed in 70.6%, 66.6%, and 34.4% of the cases, respectively. The mean of the follow-up period was 3.7 ± 1.8 years in all patients. The results of the Kaplan–Meier method revealed 1-, 3-, 5-, and 7-year rate of survival without recurrence as 96.4%, 78.4%, 66.3%, and 54.8%, respectively. There was a significant relationship between survival without recurrence and histology grade (hazard ratio [HR] = 1.66, P = 0.009), neural invasion (HR = 1.74, P = 0.006), and progesterone receptors (HR = 0.69, P = 0.031). Conclusion: In this study, the rate of survival without recurrence in breast cancer was 54.8%. Among factors, histology grade and neural involvement at the time of diagnosis increased the chance of recurrence and progesterone receptors caused a longer interval between diagnosis and recurrence.


Beiki O, Hall P, Ekbom A, Moradi T. Breast cancer incidence and case fatality among 4.7 million women in relation to social and ethnic background: A population-based cohort study. Breast Cancer Res 2012;14:R5.  Back to cited text no. 1
Naghshvar F, Torabizadeh ZH, Emadian O, Zare A, Ghahremani M. Status of expression of estrogen, progesterone, and HER-2 receptors in patients with invasive breast cancer. J Gorgan Univ Med Sci 2007;8:64-7.  Back to cited text no. 2
Kadivar M, Rezaei M, Jadidfard R, Joulaee A. Evaluation of histopathology and biologic markers in premenopausal (under 40 years) and postmenopausal (over 60 years) women with breast cancer in hazrate-e-rasoul and Atieh hospitals. J Iran Univ Med Sci 2010;17:54-60.  Back to cited text no. 3
Kolahdoozan S1, Sadjadi A, Radmard AR, Khademi H. Five common cancers in Iran. Arch Iran Med 2010;13(2):143-6.  Back to cited text no. 4
Radmard AR. Five common cancers in Iran. Arch Iran Med 2010;13:143-6.  Back to cited text no. 5
Akbari ME, Mozaffar M, Heidari A, Zirakzadeh H, Akbari A, Akbari M, et al. Recurrence and survival effect in breast conserving surgery: What are the predictive and/or prognostic factors? Iran J Cancer Prev 2011;4:49-54.  Back to cited text no. 6
Crowe JP Jr., Gordon NH, Antunez AR, Shenk RR, Hubay CA, Shuck JM. Local-regional breast cancer recurrence following mastectomy. Arch Surg 1991;126:429-32.  Back to cited text no. 7
Fakheri T, Najafi B, Fadakar Soogheh GH. Relationship between HER-2 and other clinical pathological diagnostic criteria in breast cancer patients. J Guilan Univ Med Sci 2006;15:21-7.  Back to cited text no. 8
Ensani F, Hajsadeghi N. Evaluation of predictive and prognostic factors and their effects on survival rate in a group of patients with breast carcinoma and long term follow up in cancer institute. Iran J Surg 2005;13:69-76.  Back to cited text no. 9
Mofid B, Jalali Nodoushan MR, Kiani L, Zayeri F. Association of evaluation of relation between HER2 proto-oncogen with prognostic factors of breast cancer. Res Med 2004;28:29-32.  Back to cited text no. 10
Callahan R1, Hurvitz S. Human epidermal growth factor receptor-2-positive breast cancer: Current management of early, advanced, and recurrent disease. Curr Opin Obstet Gynecol 2011;23(1):37-43.  Back to cited text no. 11
Kheradmand AA, Ranjbarnovin N, Khazaeipour Z. Postmastectomy locoregional recurrence and recurrence-free survival in breast cancer patients. World J Surg Oncol 2010;8:30.  Back to cited text no. 12
Mousavi Naeini SM, Mofid B, Mohebi HA, Mehmannavaz M, Khousheyni S. Comparison of local recurrence, metastasis and survival rate between two surgical approaches in clinical stage I and II in breast cancer. Kowsar Med J 2009;14:89-94.  Back to cited text no. 13
Brewster AM, Hortobagyi GN, Broglio KR, Kau SW, Santa-Maria CA, Arun B, et al. Residual risk of breast cancer recurrence 5 years after adjuvant therapy. J Natl Cancer Inst 2008;100:1179-83.  Back to cited text no. 14
Nojoumi M, Mirfakhraei R, Hosseini N. Relationship between hormonal factors and breast cancer. Hakim J 2004;7:19-25.  Back to cited text no. 15
Bourgier C1, Pessoa EL, Dunant A, Heymann S, Spielmann M, Uzan C, et al. Exclusive alternating chemotherapy and radiotherapy in nonmetastatic inflammatory breast cancer: 20 years of follow-up. Int J Radiat Oncol Biol Phys 2012;82(2):690-5.  Back to cited text no. 16
Le Scodan R1, Selz J, Stevens D, Bollet MA, de la Lande B, Daveau C, et al. Radiotherapy for stage II and stage III breast cancer patients with negative lymph nodes after preoperative chemotherapy and mastectomy. Int J Radiat Oncol Biol Phys 2012;82(1):e1-7.  Back to cited text no. 17
Zhang YJ, Sun GQ, Chen J, Chen J, Huang XB, Lin HX, et al. Postmastectomy locoregional recurrence and survival in early stage breast cancer patients with one to three axillary lymph node metastases. Ai Zheng 2009;28:395-401.  Back to cited text no. 18
Ragaz J1, Olivotto IA, Spinelli JJ, Phillips N, Jackson SM, Wilson KS, et al. Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial. J Natl Cancer Inst. 2005 Jan 19;97(2):116-26.  Back to cited text no. 19
Clark GM, Sledge GW Jr., Osborne CK, McGuire WL. Survival from first recurrence: Relative importance of prognostic factors in 1,015 breast cancer patients. J Clin Oncol 1987;5:55-61.  Back to cited text no. 20
Fathi T, Jabarzadeh S, Mojahedi S, Mazloom SR. Assessment of certain breast cancer risk factors during reproductive age in women in Mashhad (2002-2003). J Iran Univ Med Sci 2004;11:577-86.  Back to cited text no. 21
Hajihosseini M, Faradmal J, Sadighi-Pashaki A. Survival Analysis of Breast cancer patients after surgery with an intermediate event: Application of illness-death model. Iran J Public Health 2015;44:1677-84.  Back to cited text no. 22
Karimi A, Delpisheh A, Sayehmiri K, Saboori H, Rahimi E. Predictive factors of survival time of breast cancer in Kurdistan province of Iran between 2006-2014: A cox regression approach. Asian Pac J Cancer Prev 2014;15:8483-8.  Back to cited text no. 23
Hashemi M, Ghavami S. Effects of estradiol, progesterone and testosterone on proliferation of human breast cancer cell lines. Zahedan J Res Med Sci 2005;7:25-9.  Back to cited text no. 24